オプションチェーンは、Mersana Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Mersana Therapeuticsの市場センチメントを評価します。.

Mersana Therapeutics (NASDAQ:MRSN) 株価情報, オプションチェーン

Mersana Therapeutics

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics Inc

Oppenheimer analyst Colin Rusch downgrades First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) from Outperform to Perform.

News

Downgrades

Analyst Ratings

FSLR

Oppenheimer Downgrades First Solar to Perform

UBS analyst Batya Levi maintains American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) with a Buy and raises the price target from $245 to $250.

Price Target

UBS Maintains Buy on American Tower, Raises Price Target to $250

Needham analyst Bernie McTernan reiterates Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Buy and maintains $60 price target.

Reiteration

ETSY

Needham Reiterates Buy on Etsy, Maintains $60 Price Target

Newmark Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRK#NASDAQ">NMRK</a>) affirms FY2025 Adj EPS guidance from $1.40-$1.50 to $1.40-$1.50 vs $1.41 analyst estimate. Affirms FY2025 sales outlook from $2.90 billion-$3.10 billion to $2.90 billion-$3.10 billion vs $2.99 billion estimate.

Guidance

NMRK

Newmark Group Affirms FY2025 Adj EPS Guidance Of $1.40-$1.50 vs $1.41 Est;  Sales Guidance of $2.90B-$3.10B vs $2.99B Est

Canaccord Genuity analyst Joseph Vafi maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Buy and maintains $96 price target.

PYPL

Canaccord Genuity Maintains Buy on PayPal Holdings, Maintains $96 Price Target

TD Securities analyst Andrew Charles reiterates Yum Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) with a Hold and maintains $158 price target.

TD Securities Reiterates Hold on Yum Brands, Maintains $158 Price Target

Mizuho analyst Vijay Rakesh maintains Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) with a Neutral and lowers the price target from $50 to $34.

SMCI

Mizuho Maintains Neutral on Super Micro Computer, Lowers Price Target to $34

Barrington Research analyst Patrick Sholl maintains Lions Gate Enter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>) with a Outperform and maintains $12 price target.

Lions Gate Entertainment Corporation Class A Voting Shares

LGF/A

Barrington Research Maintains Outperform on Lions Gate Enter, Maintains $12 Price Target

Stephens &amp; Co. analyst Jim Salera reiterates Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Overweight and maintains $385 price target.

WING

Stephens & Co. Reiterates Overweight on Wingstop, Maintains $385 Price Target

Newmark Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRK#NASDAQ">NMRK</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.19 by 10.53 percent. This is a 40 percent increase over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $665.50 million which beat the analyst consensus estimate of $606.14 million by 9.79 percent. This is a 21.78 percent increase over sales of $546.50 million the same period last year.

Earnings

Earnings Beats

Newmark Group Q1 Adj. EPS $0.21 Beats $0.19 Estimate, Sales $665.50M Beat $606.14M Estimate

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is currently trading around the 552.50 level. For the bulls to maintain control, a push higher toward 553.66 would be a key early signal. If buyers can sustain strength above this area, the next leg higher targets 555.11, which would need to act as a firm intraday floor. Sustained buying activity could then drive price toward 556.27, and if momentum carries, we may see the high bull objective achieved at 557.44.
If 552.50 fails to hold as a base, we'll be watching 551.33 for signs of bearish intent. A break below that with strong downside pressure would shift focus to 550.45. Should sellers continue dominating, we'd expect a flush into 549.67. If that level can't stabilize the tape, a slide to our lowest bear objective of 549.00 becomes likely.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is currently rotating near 471.33. Bulls will want to see this level firmly supported to confirm strength. If price can base above, we'll look for an advance into 474.66. Continued bullish drive could open the door for 476.85 to be challenged, with 479.03 as the next milestone in a strong tape. The high bull target for today is 481.73 if momentum holds steady.
On the other side, if buyers can't keep 471.33 intact, we'll look for sellers to lean on 469.27. Continued weakness would likely lead to a test of 467.60. Should the sell-side pressure deepen, 465.93 becomes a critical spot to watch. If that area gives way, the low bear target sits at 463.56 for today's auction.
Apple Inc. (AAPL)
Apple is currently hovering around the 209.81 level. Bulls need to defend this level early and push toward 211.12 for confirmation of strength. If that level converts to support, look for a grind higher to 212.44. With solid momentum, Apple could move into the 214.07 zone, which is our upside target if buying continues throughout the session.
If 209.81 breaks down during the regular session, the first line of defense for the bulls is at 208.81. Failure to hold that opens the door for 207.93 to come into play. If sellers continue to apply pressure, a break below 207.18 could send price lower toward our downside target of 206.55.
Microsoft Corp. (MSFT)
Microsoft is auctioning around 394.46 to start the session. A move higher that holds this level opens the door for 395.68 to be reclaimed. If this happens, buyers may take aim at 397.65. Should momentum stay on the buy side, we'll be watching for a move into the high target zone for the day at 398.38.
If Microsoft can't defend 394.46, the bears will likely press toward 393.47. If the selling continues from there, 392.49 becomes a level of interest. Should downside momentum persist, look for a flush into 390.98. The lowest downside target for today is 389.29.
NVIDIA Corporation (NVDA)
NVIDIA is currently holding around the 107.51 level. If bulls can generate a rally from here, the first upside level of interest is 109.12. A confirmed hold above this level could lead to continuation into 109.86, with 110.73 as the next mark if buyers remain aggressive. Our highest bullish level for the day is set at 111.70.
If 107.51 doesn&#8217;t provide support, we expect sellers to test 106.30. If this zone doesn't hold, NVIDIA could lose ground to 105.23. Continued sell pressure would open up the 103.96 level. Should that break, 102.55 is our target for an extended downside move.
Alphabet Inc Class A (GOOGL)
Alphabet is currently trading around the 160.36 area. A breakout above 161.79 that finds support could bring buyers back into control. If that plays out, the next level to watch is 163.79. With continued upside strength, 165.41 serves as today's bull target.
If 160.36 can't act as a base today, watch for the bears to attempt to push price down toward 158.54. A clean break of that area would shift attention to 157.41. If downside momentum picks up steam, the next key support comes in at 156.61 as the bearish low.
Meta Platforms Inc ( META)
Meta is currently positioned near the 548.44 level. A sustained move above this could invite buyers to target 553.05. If bulls maintain control and volume flows remain positive, we could see price march up to 559.29. The most aggressive upside scenario today would have Meta hitting 565.53.
Should 548.44 give out during today's trade, expect sellers to press into 541.79. If this zone doesn't slow the bleeding, 537.68 becomes the next level to monitor. A break below that could trigger more weakness down into 534.33, which is today's bear target.
Tesla Inc. (TSLA)
Tesla is trading around 286.34. Bulls will want to see a drive toward 288.80 with follow-through to validate strength. If that level clears, 290.47 becomes a meaningful next level. With continued buying across the board, Tesla could rally into 293.21. If the tape stays hot, the high bull target is set at 294.60.
If 286.34 fails as a base, Tesla could see early pressure into 283.95. A breakdown there might lead to further selling into 281.32. If sellers sustain control, the move could extend to 279.43, marking our deepest bear target for the day.
Final Word:&nbsp;
Today's trading session is packed with major macroeconomic catalysts, starting with the ADP Non-Farm Employment Change at 8:15AM ET. Shortly after, at 8:30AM ET, traders will digest Q1 Advance GDP, GDP Price Index, and Employment Cost Index—all of which could meaningfully shift sentiment. Then at 10AM ET, March's Core PCE Price Index and Pending Home Sales data will be released, further adding to the volatility cocktail.
With this much critical economic data front-loaded into the session, traders should be prepared for swift directional moves, increased volume, and rapid shifts in sentiment. Patience and discipline will be key—especially for those trading during the first 90 minutes. Size appropriately, respect your risk, and be ready to react quickly. Good luck!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it&#8217;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

Pre-Market Outlook

Trading Ideas

How To Trade SPY, And Top Tech Stocks As US Economy Shrinks In Q1 Fueling Recession Fears

Yum Brands CFO Reportedly Says On Conference Call That They Expect Q2 Profit Growth To Be Lower Due To One-Time Expenses

<ul>
<li>Waiver exempts NRx from paying a $4.3 million New Drug Application filing fee under the Prescription Drug User Fee Act (PDUFA)</li>
<li>Company is on track for Q2 2025 completion of NDA filing and PDUFA date by year end with currently available corporate resources</li>
<li>NRX-100, together with NRX-101, was granted Fast Track designation by FDA for treatment of suicidal bipolar depression in 2018</li>
<li>Company notes recent statements by Secretary of Health and Human Services regarding the public health importance of approving psychedelic drugs such as ketamine to treat suicidal depression and PTSD</li>
</ul>
MIAMI, April 30, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>, the Company", ))), today announced the grant of a filing fee waiver by the US Food and Drug Administration ("FDA") to exempt the Company from a $4.3 million fee to file its New Drug Application for NRX-100 (preservative-free ketamine). The waiver is granted at the discretion of the FDA to Small Business Entities and for drugs that are deemed to be necessary for Public Health. The Company anticipates that this waiver enables the completion of its New Drug Application for NRX-100 with currently-available corporate resources. The NDA filing is anticipated by the end of the second quarter of this year (Q2 2025).

NRXP

NRx Pharma Announces Grant Of Filing Fee Waiver By FDA To Exempt NRx From $4.3M Fee To File New Drug Application For NRX-100

Atossa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,281,056) directed to highly pure and stable enteric oral formulations comprising (Z)-endoxifen as well as therapeutic methods of using those oral formulations.
The newly granted patent includes 58 claims covering (Z)-endoxifen formulations, including various levels of purity and stability as well as methods of using those formulations. This patent provides additional support for Atossa's intellectual property portfolio surrounding its proprietary (Z)-endoxifen formulations, a potent Selective Estrogen Receptor Modulator (SERM).

Biotech

General

ATOS

Atossa Therapeutics Awarded U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations For Its (Z)-Endoxifen Portfolio

Barrington Research analyst Michael Petusky maintains Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) with a Outperform and maintains $38 price target.

OPCH

Barrington Research Maintains Outperform on Option Care Health, Maintains $38 Price Target

Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) shares are trading higher on Wednesday after the company reported <a href="https://www.benzinga.com/pressreleases/25/04/n45094898/caterpillar-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">first-quarter 2025 results</a>. Total sales and revenue for the quarter declined 9.8% year-over-year to $14.25 billion, missing the consensus of $14.66 billion.
The decrease was primarily due to a $1.1 billion drop in sales volume and a $250 million unfavorable price realization, largely impacted by changes in dealer inventories.
Dealer inventory increased by $100 million in the quarter, compared to a $1.4 billion increase a year ago.
CAT&#8217;s adjusted earnings were $4.24 per share, compared to $5.60 a year ago and below the consensus of $4.35.
Operating profit fell 26.7% to $2.579 billion, primarily due to a $652 million impact from lower sales volume and $250 million from unfavorable price realization.
The operating profit margin was 18.1%, down from 22.3% a year ago. The adjusted operating profit margin was 18.3% compared with 22.2% a year ago.
Enterprise operating cash flow was $1.3 billion, and the company ended the quarter with $3.6 billion in enterprise cash. The company spent $3.7 billion on stock repurchases and $0.7 billion on dividends.
&nbsp;&#8220;Our strong balance sheet allowed us to deploy over $4 billion to shareholders through share repurchases and dividends during the quarter,&#8221; command Chairman and CEO Jim Umpleby.
&#8220;Our strategy for long-term profitable growth is delivering results, which reflect the benefits of our diverse portfolio and end markets,&#8221; stated incoming CEO Joe Creed.
The revenue of the machinery, energy, and transportation segment declined 11% YoY, with construction Industries down 19%, Resource Industries down 10%, energy and transportation down 2%, and other segments down 17%.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44740051/general-electric-and-caterpillar-lead-xli-pullback-whats-going-on" rel="noreferrer noopener">General Electric And Caterpillar Lead XLI Pullback: What&#8217;s Going On?</a>
Q2 Outlook: Caterpillar expects sales and revenues to be similar to 2024. The adjusted operating profit margin is expected to be lower than YoY, mainly due to lower price realization before considering tariff impact.
Tariffs are expected to create an additional cost headwind of $250M to $350M in Q2, net of initial mitigation actions and cost controls.
2025 Outlook Pre-tariff scenario: Caterpillar expects Full-year sales and revenues to be flat compared to 2024, better than the previous slight decline forecast.
Adjusted operating profit margin is expected to be in the top half of the annual target range, and ME&amp;T&#8217;s free cash flow is expected to be in the top half of the annual target range.
2025 Outlook, <a target="_blank" href="https://s25.q4cdn.com/358376879/files/doc_financials/2025/q1/1Q-2025-Analyst-Slide-Deck-Final.pdf" rel="noreferrer noopener">Alternative Scenario</a> (with Tariff Impact and Negative Economic Growth): CAT expects full-year sales and revenues to be down slightly compared to 2024, which aligns with previous expectations.
The adjusted operating profit margin and ME&amp;T&#8217;s free cash flow are expected to be within the annual target range.
Price Action: CAT is trading higher by 3.12% at $317 premarket at the last check Wednesday.
Photo via Shutterstock

Movers

Caterpillar Warns Of $250 Million To $350 Million Tariff Hit After Q1 Profit Miss

Shift4 Payments, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) ("Shift4" or the "Company"), a leader in integrated payments and commerce technology, today announced the launch of an underwritten public offering (the "Offering") of 7,500,000 shares of Series A Mandatory Convertible Preferred Stock, par value $0.0001 per share ("Mandatory Convertible Preferred Stock"), of the Company, subject to market conditions. Shift4 expects to grant to the underwriters of the Offering a 30-day option to purchase up to 1,125,000 additional shares of Mandatory Convertible Preferred Stock solely to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions. Shift4 intends to use the net proceeds from the Offering, proposed additional permanent debt financing of up to $1,735.0 million, together with cash on its balance sheet for (i) the payment of the cash consideration due in respect of Shift4's previously announced acquisition of Global Blue Group Holding AG (the "merger") and related fees, costs and expenses and/or (ii) general corporate purposes, including repayment of debt, other strategic acquisitions and growth initiatives.
Goldman Sachs &amp; Co. LLC, Citigroup Global Markets Inc., Wells Fargo Securities, LLC, Barclays Capital Inc., Citizens JMP Securities, LLC, and Santander US Capital Markets LLC are acting as joint book-running managers for the Offering.
The Mandatory Convertible Preferred Stock is expected to have a liquidation preference of $100.00 per share. Unless previously converted or redeemed, each outstanding share of Mandatory Convertible Preferred Stock will automatically convert, for settlement on or about May 1, 2028 (subject to postponement in certain limited circumstances), into a variable number of shares of Shift4's Class A common stock, par value $0.0001 per share. Shift4 will have the right to redeem all, but not less than all, of the Mandatory Convertible Preferred Stock if certain non-occurrence events occur with respect to the merger, including if the merger is not completed within a specified period of time. The dividend rate, conversion terms and other terms of the Mandatory Convertible Preferred Stock will be determined at the time of pricing of the Offering and remain subject to change. The completion of the Offering is not contingent upon the consummation of the merger, which, if consummated, will occur subsequent to the completion of the Offering.

Offerings

FOUR

Shift4 Payments Launches Public Offering Of 7.5M Series A Mandatory Convertible Preferred Stock To Fund Global Blue Acquisition And Growth Initiatives

Mizuho analyst Siti Panigrahi initiates coverage on OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) with a Outperform rating and announces Price Target of $30.

Initiation

Mizuho Initiates Coverage On OneStream with Outperform Rating, Announces Price Target of $30

Barrington Research analyst Alexander Paris maintains American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) with a Outperform and maintains $24 price target.

APEI

Barrington Research Maintains Outperform on American Public Education, Maintains $24 Price Target

Keybanc analyst Sophie Karp downgrades First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) from Sector Weight to Underweight and announces $100 price target.

Keybanc Downgrades First Solar to Underweight, Announces $100 Price Target

Press Releases

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

Health Care

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

Mersana Therapeutics to Present at Upcoming Investor Conferences

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

Comments

Mersana Therapeutics

Mersana Therapeutics (MRSN) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル